<DOC>
	<DOC>NCT00866203</DOC>
	<brief_summary>The study is planned to compare the outcome of aggressive NHL patients in partial remission after four courses of front-line therapy, randomly assigned to receive either additional four courses of the same regimen or a modified HDS program.</brief_summary>
	<brief_title>HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Newly diagnosed, untreated patients with histologically documented aggressive lymphoma; Age between 18 and 65 years; Clinical stage at diagnosis: I A bulky IV B; Reduction of tumoral masses, after four courses of induction therapy, between 50 and 75%; Serum negativity for HIV, HbsAg and HCV; ECOG performance status 0 through 4; Adequate bone marrow function; Adequate renal and hepatic functions; Left ventricular ejection fraction (LVEF) &gt; 50%; No previous malignant disease; No previous chemoradiotherapy; No cerebral or CNS involvement, assessed by clinical history, physical examination and CSF examination through lumbar puncture; Written informed consent given at time of randomization. Clinical stage I no bulky, or CS IIAB with less than three sites of disease involved; Patients with CR, unconfirmed complete remission (uCR), very good PR (&gt;75%) and clinical response less than 50%, as defined by Cheson et al., following four courses of induction therapy; Tumor involvement of CNS (except patients with peridural masses without liquor involvement , who can be enrolled in this study); Indolent lymphoma transformed in more aggressive histologic type, even if never previously treated; Aggressive nonHodgkin's lymphoma in pretransplanted patient; Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension, (resting diastolic blood pressure &gt; 115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class IIIIV; Left ventricular ejection fraction (LVEF) &lt; 50%; Evidence of any severe active acute or chronic infection; Concurrent malignancy of history of other malignancy, except basal cell carcinoma of the skin (BCC) and in situ cervical carcinoma (CIN); myelodisplastic syndrome; HbsAg, HIVpositive, or HCVRNApositive patients; Patient with psychiatric, or any disorder that compromises ability to give truly informed consent for participation in this study; Pregnant woman; potential childbearing women can be enrolled if adequate contraceptive precautions are used before entering this trial and for the duration of the trial; Concerns for patient's compliance with the protocol procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>